Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection.

Ohs I, Windmann S, Wildner O, Dittmer U, Bayer W.

PLoS One. 2013 Dec 4;8(12):e82528. doi: 10.1371/journal.pone.0082528. eCollection 2013.

2.

Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, Uberla K, Dittmer U, Wildner O.

J Virol. 2010 Feb;84(4):1967-76. doi: 10.1128/JVI.01840-09. Epub 2009 Dec 9.

3.

Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.

Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, Schimmer S, Groitl P, Wolf H, Berry CM, Uberla K, Dittmer U, Wildner O.

Retrovirology. 2011 Sep 26;8:75. doi: 10.1186/1742-4690-8-75.

4.

Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.

Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O.

Vaccine. 2008 Jan 30;26(5):716-26. Epub 2007 Dec 5.

PMID:
18160188
5.

Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.

Lietz R, Bayer W, Ontikatze T, Johrden L, Tenbusch M, Storcksdieck Genannt Bonsmann M, Uberla K, Dittmer U, Wildner O.

J Virol. 2012 Feb;86(3):1706-16. doi: 10.1128/JVI.06244-11. Epub 2011 Nov 16.

6.

Co-immunization of mice with a retroviral DNA vaccine and GITRL-encoding plasmid augments vaccine-induced protection against retrovirus infection.

Dittmer U, Werner T, Kraft AR.

Viral Immunol. 2008 Dec;21(4):459-67. doi: 10.1089/vim.2008.0046.

PMID:
19115935
7.

Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease.

Kawabata H, Niwa A, Tsuji-Kawahara S, Uenishi H, Iwanami N, Matsukuma H, Abe H, Tabata N, Matsumura H, Miyazawa M.

Int Immunol. 2006 Jan;18(1):183-98. Epub 2005 Dec 13.

PMID:
16352628
8.

Protection of mice against Friend retrovirus infection by vaccination with antigen-loaded, spleen-derived dendritic cells.

Reuter T, Heldmann M, Schimmer S, Schepers K, Dittmer U.

Vaccine. 2004 Jul 29;22(21-22):2686-9.

PMID:
15246598
9.
10.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

12.
13.
15.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.

Vaccine. 2015 Oct 5;33(41):5406-14. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.

16.
17.

Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.

Thomas MA, Song R, Demberg T, Vargas-Inchaustegui DA, Venzon D, Robert-Guroff M.

PLoS One. 2013 Oct 15;8(10):e76344. doi: 10.1371/journal.pone.0076344. eCollection 2013.

18.

Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Dittmer U, Peterson KE, Messer R, Stromnes IM, Race B, Hasenkrug KJ.

J Virol. 2001 Jan;75(2):654-60.

19.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

20.

Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.

Knuschke T, Rotan O, Bayer W, Sokolova V, Hansen W, Sparwasser T, Dittmer U, Epple M, Buer J, Westendorf AM.

Retrovirology. 2016 Apr 14;13:24. doi: 10.1186/s12977-016-0258-9. Review.

Supplemental Content

Support Center